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Background. Single inhibition of the Toll-like receptor 4 (TLR4)–MD2 complex failed in treatment of sepsis. CD14 is a core-
ceptor for several TLRs, including TLR4 and TLR2. The aim of this study was to investigate the effect of single TLR4-MD2 inhibition
by using eritoran, compared with the effect of CD14 inhibition alone and combined with the C3 complement inhibitor compstatin
(Cp40), on the bacteria-induced inflammatory response in human whole blood.
Methods. Cytokines were measured by multiplex technology, and leukocyte activation markers CD11b and CD35 were mea-
sured by flow cytometry.
Results. Lipopolysaccharide (LPS)–induced inflammatory markers were efficiently abolished by both anti-CD14 and eritoran.
Anti-CD14 was significantly more effective than eritoran in inhibiting LPS-binding to HEK-293E cells transfected with CD14 and
Escherichia coli–induced upregulation of monocyte activation markers (P < .01). Combining Cp40 with anti-CD14 was significantly
more effective than combining Cp40 with eritoran in reducing E. coli–induced interleukin 6 (P < .05) and monocyte activation mark-
ers induced by both E. coli (P < .001) and Staphylococcus aureus (P < .01). Combining CP40 with anti-CD14 was more efficient than
eritoran alone for 18 of 20 bacteria-induced inflammatory responses (mean P < .0001).
Conclusions. Whole bacteria–induced inflammation was inhibited more efficiently by anti-CD14 than by eritoran, particularly
when combined with complement inhibition. Combined CD14 and complement inhibition may prove a promising treatment strat-
egy for bacterial sepsis.
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Sepsis is a severe and life-threatening systemic inflammatory re-
sponse to an infection. Despite extensive treatment with antibi-
otics and supportive therapy, morbidity and mortality due to
sepsis remain high. Escherichia coli is the leading gram-negative
bacterial cause of sepsis and Staphylococcus aureus is the most
frequently observed gram-positive bacterial cause, with the lat-
ter showing increasing incidence [1, 2]. However, the causative
agent is often unknown at the time of diagnosis and initiation of
treatment.
The current hypothesis is that the initial infection triggers
proinflammatory and antiinflammatory responses by the im-
mune system and, subsequently, may severely disturb this nor-
mally finely regulated system, leading to tissue damage, organ
failure, and ultimately death [3]. This detrimental, uncontrolled
activation might be attenuated by manipulating the inflamma-
tory process as an adjunct to antimicrobial treatment. A tempt-
ing strategy is to manipulate the early stages of inflammation by
targeting upstream recognition of pathogen-associated molecu-
lar patterns and damage-associated molecular patterns.
The complement system provides an important first-line de-
fense for protecting the body against pathogens. Recognition of
pathogens by any of the 3 initial pathways (the classical, lectin,
and alternative pathways) leads to the activation of C3 and C5,
generating C3 fragments for opsonization of bacteria and the
anaphylatoxins C3a and C5a, with a range of effector functions.
Finally, the terminal C5b-9 complex is assembled, which can
lyse bacterial membranes, especially Neisseria species. Most
bacteria are, however, killed by complement via opsonization
of C3 fragments and subsequent phagocytosis.
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Toll-like receptors (TLRs) induce responses through the acti-
vation of specific intracellular signaling pathways [4]. TLR4 and
TLR2 are the most studied receptors, with TLR4 being the key
receptor for lipopolysaccharide (LPS) from gram-negative bac-
teria and TLR2 detecting lipoproteins from gram-positive bac-
teria. CD14 serves as a coreceptor for TLR4, where it presents
the LPS molecule to the LPS-binding site on the TLR4-MD2
complex [5]. CD14 has also been shown to interact with other
TLRs, including TLR2, TLR3, TLR7, and TLR9 [6–8]. Recently,
we produced a recombinant version of the neutralizing mono-
clonal mouse anti-human CD14 antibody 18D11 [9]. This an-
tibody is endowed with a human immunoglobulin G2/4 (IgG2/
4) hybrid heavy chain and is thus inert with respect to the major
IgG effector functions (ie, complement activation and Fcγ-
receptor binding) and therefore does not deplete leukocytes.
Eritoran is a synthetic lipid A analogue that binds to the LPS
binding site on MD2 and prevents further signaling via the
TLR4-MD2 complex. Recent reports suggest that eritoran also
binds directly to CD14 and might partly inhibit the LPS-CD14
interaction [10]. Although eritoran effectively inhibits LPS-
induced inflammatory responses, no reduction in 28-day mor-
tality was achieved in a phase 3 study, in which eritoran was ad-
ministered as an adjunct to standard sepsis treatment [11].
Combined inhibition with a neutralizing CD14 antibody and
a complement inhibitor is effective in attenuating the inflamma-
tory process by inhibiting cytokine release and expression of ac-
tivation markers on leukocytes to a greater extent than single
inhibition with either agent alone [12–14]. Murine and porcine
in vivo sepsis models have demonstrated this strategy to be su-
perior to single inhibition with either of the inhibitors alone,
with respect to both attenuation of the inflammatory response
and increased survival [15–17].
The aim of the present study was to elucidate the differential
effects of eritoran and anti-CD14, alone and in combination
with a complement inhibitor, on the inflammatory process in-




Endotoxin-free Cryo tubes were purchased fromNunc (Roskilde,
Denmark). Ethylenediaminetetraacetic acid (EDTA), parafor-
maldehyde, and sterile phosphate-buffered saline (PBS) were
purchased from Sigma-Aldrich (St. Louis, Missouri). Lepirudin
(Refludan) was purchased from Celgene (Marburg, Germany).
Dimethyl sulfoxide and Alexa Fluor 488 were obtained from
Invitrogen Molecular Probes (Eugene, Oregon). Anti-CD11b-
PE (clone D12), anti-CD35-FITC (clone E11), anti-CD45-
PerCP (clone 2D1), anti-CD14-PerCP, and anti-CD14-PE
(clone MϕP9) and the isotype controls PE-mouse IgG2a (clone
X59) and FITC-mouse IgG1k (clone MOPC-21) were obtained
from Becton, Dickinson, and Company (San Jose, California).
Inhibitors
The C3-inhibitor compstatin analogue Cp40 (D-Tyr-Ile-[Cys-
Val-1MeTrp-Gln-Asp-Trp-Sar-Ala-His-Arg-Cys]-meIle) and
the control peptide (Sar-Sar-Trp[Me]-Ala-Ala-Asp-Ile-His-
Val-Gln-Arg-mIle-Trp-Ala-NH2) were produced in the lab of
one of the authors (J. D. L.), as previously described [18]. Eri-
toran (E5564) was kindly provided by Eisai (Andover, Massa-
chusetts). Recombinant anti-human CD14 IgG2/4 antibody
(r18D11) and an IgG2/4 isotype control antibody were pro-
duced in our laboratory as previously described [9].
LPS and Bacteria
Ultrapure LPS from E. coli strain 0111:B4 (smooth type) was
purchased from InvivoGen (San Diego, California) and Cy5-la-
belled for the human embryonic kidney (HEK) 293E cell–based
experiments as described previously [19]. E. coli strain LE392
with smooth LPS (ATCC 33572) and S. aureus Cowan strain
1 (ATCC 12598) were obtained from American Type Culture
Collection (ATCC; Manassas, Virginia). The bacteria were inac-
tivated by heat and counted by flow cytometry as previously de-
scribed [12, 14].
HEK-293E Cell–Based Experiments
HEK-293E cells do not express CD14, TLR4, or MD2 and were
transfected with human CD14, using GeneJuice transfection
reagent (Novagene, Darmstadt, Germany). The cells were prein-
cubated for 5 minutes with increasing doses of anti-CD14 (0.007,
0.07, and 0.7 µM), eritoran (0.1, 1, and 10 µM), or an IgG2/4 iso-
type control antibody (0.007, 0.07, and 0.7 µM) before addition
of Cy5-labeled LPS (500 ng/mL). Cy5-LPS binding to CD14 was
measured by flow cytometry after 1 hour of incubation (37°C).
The samples were washed in cold PBS twice and detached in
Accutase solution (Sigma) before the addition of 2% fetal calf
serum in PBS. The cell pellets were harvested by centrifugation
(at 470g for 5 minutes) and resuspended in PBS before analysis
on a BD LSR II flow cytometer. Data analysis was performed with
FlowJo software (Ashland, Oregon). Results are given as mean
fluorescence intensity.
Whole-Blood Model of Inflammation
The whole-blood model is an in vitro system for studying in-
flammation activity and has been described in detail previously
[20]. Briefly, blood specimens were collected from healthy vol-
unteers (both sexes were evaluated, with an age range of 30 to
58 years) and anticoagulated with the thrombin inhibitor lepir-
udin (50 µg/mL). Blood specimens were preincubated with the
inhibitors compstatin Cp40 (20 µM), anti-CD14 (0.1 µM), eri-
toran (1 µM), control peptide (20 µM), IgG2/4 isotype control
antibody (0.1 µM), or PBS in sterile polypropylene tubes for 5
minutes (37°C). The optimal inhibitor concentrations were deter-
mined in separate dose-response experiments (data not shown).
The concentration of eritoran was comparable to the plasma
concentration in a phase 2 clinical study [21], using a similar
dose as that in the ACCESS sepsis trial [11]. Subsequently,
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blood specimens were stimulated with LPS, E. coli, or S. aureus
at concentrations specified below and incubated with gentle ro-
tation (at 37°C) for the appropriate time, depending on which
inflammation markers were to be studied.
Cytokine Analysis
LPS (10 ng/mL), E. coli (1 × 106 bacteria/mL), or S. aureus
(1 × 107 bacteria/mL) were added, and samples were incubated
for 120 minutes. After incubation, EDTA was added (10 mM),
and the samples placed on ice and centrifuged (at 1800g for
15 minutes at 4°C); the resulting plasma was frozen (−70°C)
until further analyzed. Analyses of tumor necrosis factor
(TNF), interleukin 1β (IL-1β), interleukin 6 (IL-6), and inter-
leukin 8 (IL-8) were performed with Bio-Plex Pro technology
(Bio-Rad Laboratories, Hercules, California), using standard
procedures from the manufacturer.
Leukocyte Activation Markers CD11b and CD35
LPS (10 ng/mL), E. coli (1 × 107 bacteria/mL), or S. aureus
(1 × 108 bacteria/mL) were added, and samples were incubated
for 20 minutes. Cells were fixed with 0.5% paraformaldehyde
and incubated with anti-CD11b-PE and anti-CD35-FITC or
with isotype controls, in addition to anti-CD14-PerCP. Samples
were lysed, centrifuged (at 300g for 5 minutes at 4°C), and
analyzed on a FACSCalibur flow cytometer. Data analysis was
performed with FlowJo software. Monocytes and granulocytes
were gated by side scatter and CD14 expression. Results are
given as median fluorescence intensity.
Phagocytosis
As previously described, whole-blood specimens were incubat-
ed with a final concentration of Alexa Fluor 488–stained E. coli
(5 × 107 bacteria/mL) and S. aureus (1 × 108 bacteria/mL) for 15
minutes, and phagocytosis was assessed by Phagotest (Glyco-
tope Biotechnology, Heidelberg, Germany), according to kit in-
structions [20]. Monocytes and granulocytes were gated by side
scatter and CD14 expression. Results are given as mean fluores-
cence intensity.
Statistical Analysis
All statistical calculations were done in Prism 5 (GraphPad, San
Diego, California). A t test was used for the HEK-293E cell exper-
iments. All whole-blood experiments were repeated with 6 differ-
ent donors, unless otherwise stated. The LPS data were analyzed
by repeated measures 1-way analysis of variance (ANOVA) of all
3 groups (LPS positive control, anti-CD14, and eritoran), with
comparison of the latter 2 groups by post hoc Bonferroni correc-
tion for selected multiple testing. The E. coli and S. aureus data
were analyzed by repeatedmeasures 1-way ANOVA of the groups
of interest (anti-CD14, eritoran, anti-CD14 plus compstatin, and
eritoran plus compstatin). Comparisons of adjacent inhibitors
were estimated by post hoc Bonferroni correction for selected
multiple testing. A P value of <.05 was considered statistically
significant. Compstatin Cp40 alone was included in the test
panel to show the contribution of complement inhibition, but
it was not included in the statistical analysis [13].
Ethics
Informed written consent was obtained from each blood donor.
The local ethical committee approved the study.
RESULTS
LPS-Induced Responses
To demonstrate the inhibitory effects of eritoran and anti-CD14
on the LPS-induced inflammatory responses, inhibition of LPS-
induced cytokine release and upregulation of CD11b and CD35
on leukocytes were tested in human whole-blood specimens
(Figure 1). Both eritoran and anti-CD14 efficiently and signifi-
cantly inhibited LPS-induced release of TNF, IL-1β, IL-6, and
IL-8 (P < .01–P < .0001; Figure 1A). Eritoran showed equivalent
(for TNF, IL-1β, and IL-6) or significantly more-effective (for
IL-8) inhibition when compared to anti-CD14 (P < .05). Simi-
larly, both inhibitors significantly attenuated the LPS-induced
increase in monocyte expression of CD11b (96% and 90% re-
duction, respectively; P < .01) and CD35 (95% and 94% reduc-
tion, respectively; P < .05; Figure 1B). Granulocytes were not
activated under these conditions, as their LPS-responsiveness
is much lower than seen for monocytes [22].
To investigate the inhibitory effects of eritoran on LPS-binding
to CD14, HEK-293E cells transfected with human CD14 were
used. The cells were preincubated with increasing doses of eritor-
an or anti-CD14 prior to LPS stimulation. Both eritoran and anti-
CD14 inhibited LPS-binding to CD14 in a dose-dependent
manner (Figure 2). However, anti-CD14 was significantly more
effective (P < .05) when comparing concentrations sufficient to
inhibit LPS-induced inflammatory responses in the whole-
blood model (0.07 µM anti-CD14 and 1 µM eritoran).
The negative controls (IgG2/4 isotype control antibody and
control peptide) did not inhibit any of the LPS readouts (data
now shown).
E. coli–Induced Inflammatory Responses
To investigate the effects of eritoran alone, anti-CD14 alone, and
the combination of each with the C3 inhibitor compstatin Cp40
in a more complex model of inflammation, E. coli was used to
stimulate whole-blood specimens. Cytokine analysis showed
that inhibition with anti-CD14 alone or eritoran alone markedly
attenuated the release of TNF, IL-1β, IL-6, and IL-8, without sig-
nificant differences between the 2 inhibitors (Figure 3). The com-
bination of anti-CD14 and compstatin Cp40 inhibited the release
of all cytokines down to background levels. For IL-6, this combi-
nation was significantly more efficient than the combination of
eritoran and compstatin Cp40 (P < .05).
Inhibition with anti-CD14 alone reduced the E. coli–induced
upregulation of monocyte CD11b and CD35 by 82% and 83%,
respectively, and was significantly more effective than inhibition
with eritoran alone (33% reduction [P < .001] and 25%
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reduction [P < .01], respectively; Figure 4). The combination of
anti-CD14 and compstatin Cp40 reduced levels of both recep-
tors to background levels, significantly more efficient than the
combination of eritoran and compstatin Cp40 (45% and 34%
reductions, respectively; P < .01). In contrast to monocytes, up-
regulation of granulocyte CD11b and CD35 was complement
dependent (86% and 83% reductions by compstatin Cp40, re-
spectively) and only moderately affected by inhibition with
anti-CD14 alone (40% and 30% reductions, respectively) or eri-
toran alone (28% and 15% reductions, respectively; Figure 4).
The combined treatments reduced the upregulation of both re-
ceptors down to background levels.
Figure 1. Effects of anti-CD14 and eritoran on lipopolysaccharide (LPS)–induced inflammation markers in human whole-blood specimens. A, Tumor necrosis factor (TNF),
interleukin 1β (IL-1β), interleukin 6 (IL-6), and interleukin 8 (IL-8) release in response to incubating human whole-blood specimens with ultrapure LPS (10 ng/mL) for 120 minutes
after preincubation with phosphate-buffered saline (PBS), anti-CD14, or eritoran. B, CD11b and CD35 expression on monocytes in response to stimulation of human whole-blood
specimens with ultrapure LPS for 20 minutes after preincubation with PBS, anti-CD14, or eritoran. Data are presented as box plots, with upper and lower limits of the boxes
representing interquartile ranges, whiskers representing and 10th and 90th percentiles, horizontal lines within boxes representing median values, and vertical lines within
boxes representing mean values; data are from 6 independent experiments, using 6 different donors. Statistical significance was estimated by using repeated measures 1-way
analysis of variance (top line), and comparison between anti-CD14 and eritoran was estimated by post-hoc Bonferroni correction for selected multiple testing (closed line).
*P < .05, **P < .01, ***P < .001, and ****P < .0001. Abbreviations: MFI, median fluorescence intensity; NS, nonsignificant.
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Figure 2. Effects of anti-CD14 and eritoran on lipopolysaccharide (LPS)–binding to membrane-bound CD14. A, Human embryonic kidney 293E cells transfected with human
CD14 were incubated with Cy5-labeled LPS after preincubation with increasing doses of anti-CD14 (aCD14), eritoran, or a control antibody. Data are shown as mean fluores-
cence intensity (MFI) and presented as mean ± standard error of the mean of 3 experiments. Statistical significance was estimated by a parametric t test between anti-CD14
0.07 µM and eritoran 1 µM data. *P < .05. B, Flow cytometry histograms showing data from one of the 3 virtually identical experiments presented in panel A.
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The negative controls did not inhibit any of the E. coli–
induced inflammatory readouts (data not shown).
S. aureus–Induced Inflammatory Responses
We next investigated whether eritoran alone, anti-CD14 alone,
and the combination of each with the complement inhibitor
Cp40 would have similar effects in a model involving gram-
positive induction of inflammation. S. aureus was used in the
same experimental design as described above for E. coli.
Cytokine analysis showed that inhibition of TNF, IL-1β, IL-6,
and IL-8 was dependent on complement to a greater extent for
S. aureus than for E. coli. The attenuating effect of single inhi-
bition with anti-CD14 or eritoran was minimal, without signifi-
cant differences between the 2 inhibitors (Figure 5). The
combination of anti-CD14 and compstatin Cp40 reduced the
cytokine release by 60%–75%, also showing a tendency of stron-
ger attenuation than the combination of eritoran and compsta-
tin Cp40, although these differences did not reach statistical
significance.
Upregulation of monocyte CD11b and CD35 by S. aureus
was reduced significantly more by the combination of anti-
CD14 and compstatin Cp40 (70% and 75%, respectively) than
by the combination of eritoran and compstatin Cp40 (47% and
34% reduction, respectively; P < .01; Figure 6). Inhibition with
either anti-CD14 alone or eritoran alone showed no inhibitory
effect. Upregulation of granulocyte CD11b and CD35 was
mainly complement dependent and reduced by 92% and 78%,
respectively, by compstatin Cp40 alone (Figure 6). No further
effect was seen by the combined treatments, and again, single
inhibition with either anti-CD14 or eritoran showed no inhib-
itory effect.
The negative controls did not inhibit any of the S. aureus–
induced inflammatory readouts (data not shown).
Bacterial Phagocytosis
E. coli
Monocyte phagocytosis of E. coli was reduced by 24% by in-
hibition with anti-CD14 alone and was significantly more
Figure 3. Inhibition of Escherichia coli–induced cytokine release in human whole blood. Tumor necrosis factor (TNF), interleukin 1β (IL-1β), interleukin 6 (IL-6), and interleukin
8 (IL-8) release in response to incubating human whole-blood specimens with heat-inactivated E. coli (1 × 106 bacteria/mL) for 120 minutes after preincubation with phosphate-
buffered saline (PBS), compstatin (Cp40), anti-CD14, eritoran, anti-CD14 plus compstatin, or eritoran plus compstatin. Data are presented as box plots, with upper and lower
limits of the boxes representing interquartile ranges, whiskers representing and 10th and 90th percentiles, horizontal lines within boxes representing median values, and
vertical lines within boxes representing mean values; data are from 6 independent experiments, using 6 different donors. Statistical significance between the inhibitors of
interest was estimated by using repeated measures 1-way analysis of variance (top line), and comparison between adjacent inhibitors was estimated by post-hoc Bonferroni
correction for selected multiple testing (closed lines). *P < .05, **P < .01, ***P < .001, and ****P < .0001. Abbreviation: NS, nonsignificant.
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effective than inhibition with eritoran alone (no reduction;
P < .01; Figure 7A). The combination of anti-CD14 and comp-
statin Cp40 reduced the phagocytosis by 79%, which was not
significantly different from the combination of eritoran and
compstatin Cp40 (57% reduction). Granulocyte phagocytosis
was only minimally affected by inhibition with anti-CD14
alone or eritoran alone (11% and 6% reduction, respectively;
Figure 7A). The combination of anti-CD14 and compstatin
Cp40 reduced phagocytosis by 90%, similar to the combination
of eritoran and compstatin Cp40 (87% reduction).
S. aureus
Monocyte phagocytosis of S. aureus was complement depen-
dent (75% reduction by compstatin Cp40; Figure 7B). Single in-
hibition with anti-CD14 showed a 20% reduction and did not
significantly differ from eritoran (7% reduction). The combina-
tion of anti-CD14 and compstatin Cp40 (93% reduction)
showed a minor additional inhibitory effect, although not stat-
istical significant, compared to the combination of eritoran and
compstatin Cp40 (76% reduction). Granulocyte phagocytosis
was completely complement dependent, being reduced to back-
ground levels by compstatin Cp40 alone, without any effect of
single inhibition of anti-CD14 or eritoran (Figure 7B).
Eritoran Versus the Combined Inhibition of CD14 and Complement
Since eritoran was used to treat sepsis but failed, we compared
the effects of eritoran alone with that of combined anti-CD14
and complement inhibition, which we propose as an alternative
treatment approach [15, 17]. Noteworthy, for 18 of 20 readouts
reported for the bacteria-induced inflammatory responses (Fig-
ures 3–7), the combination of anti-CD14 and compstatin Cp40
was substantially more efficient than inhibition with eritoran
alone (P < .05–P < .0001; mean P < .0001).
DISCUSSION
In the present study, we have demonstrated that, although eri-
toran was an effective inhibitor of LPS-induced inflammation, it
showed no effect on E. coli–induced leukocyte activation mark-
ers or inflammation induced by S. aureus. Anti-CD14 showed a
broader inhibitory effect than eritoran, as it also efficiently
Figure 4. Inhibition of Escherichia coli–induced upregulation of CD11b and CD35 on monocytes and granulocytes in human whole-blood specimens. Upregulation of CD11b
and CD35 on monocytes and granulocytes in response to incubating human whole-blood specimens with heat-inactivated E. coli (1 × 107 bacteria/mL) for 20 minutes after
preincubation with phosphate-buffered saline (PBS), compstatin (Cp40), anti-CD14, eritoran, anti-CD14 plus compstatin, or eritoran plus compstatin. Data are shown as median
fluorescence intensity (MFI). Data presentation and statistics are as described in the legend to Figure 3. **P < .01, ***P < .001, and ****P < .0001. Abbreviation: NS,
nonsignificant.
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inhibited monocyte activation by E. coli. The addition of a com-
plement inhibitor was necessary to inhibit granulocyte activa-
tion and S. aureus inflammatory responses. The combined
inhibition of CD14 and complement was significantly more ef-
ficient than the combination of eritoran and complement inhi-
bition, especially in terms of monocyte activation.
In addition to blocking the TLR4-MD2 complex, eritoran has
also been reported to bind to soluble CD14, preventing further
ligand binding to MD2 [10]. We here show that even though
eritoran attenuated LPS-binding to membrane-bound CD14
dose dependently, anti-CD14 inhibited the LPS-binding much
more effectively.
Both anti-CD14 and eritoran showed efficient attenuating ef-
fects on E. coli–induced cytokine responses, in line with the
LPS-driven activation of TLR4. However, adding a complement
inhibitor increased the effect. Moreover, there was a trend indi-
cating that the combination of anti-CD14 and compstatin Cp40
was more effective than the combination of eritoran and comp-
statin Cp40, with the difference reaching significance for IL-6.
Eritoran had minimal effect on S. aureus–induced cytokine
responses. The different effects of eritoran on E. coli– and S. au-
reus–induced inflammation are not surprising, since S. aureus
does not contain LPS and is thought to activate the inflamma-
tory system mainly through TLRs other than TLR4, particularly
TLR2 and TLR8, and the complement system [14, 23–25]. The
addition of a complement inhibitor was necessary to efficiently
inhibit S. aureus–induced cytokine release.
Leukocyte activation is a hallmark of bacterial infection.
CD11b and CD35 have been shown to increase significantly
on monocytes and neutrophils in patients with bacterial infec-
tions and sepsis, compared with healthy controls [26, 27].
Monocyte activation by gram-negative bacteria has previously
been shown to be largely CD14 dependent [28]. This observa-
tion has been attributed to LPS-driven activation of TLR4.
In the current study, eritoran completely abolished LPS-
induced expression of the 2 leukocyte activation markers CD11b
and CD35 on monocytes but, surprisingly, had almost no effect
on the E. coli–induced expression. In contrast to eritoran, inhibi-
tion with anti-CD14 alone significantly and efficiently reduced
the expression of these activation markers. This suggests that
Figure 5. Inhibition of Staphylococcus aureus–induced cytokine release in human whole-blood specimens. Tumor necrosis factor (TNF), interleukin 1β (IL-1β), interleukin 6
(IL-6), and interleukin 8 (IL-8) release in response to incubation of human whole-blood specimens with heat-inactivated S. aureus (1 107 bacteria/mL) for 120 minutes after
preincubation with phosphate-buffered saline (PBS), compstatin (Cp40), anti-CD14, eritoran, anti-CD14 plus compstatin, or eritoran plus compstatin. Data presentation and
statistics are as described in the legend to Figure 3. **P < .01, ***P < .001, and ****P < .0001. Abbreviation: NS, nonsignificant.
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redundant pathways of CD11b and CD35 upregulation that are
independent of soluble LPS and TLR4-MD2 but dependent on
CD14 may be activated by whole bacteria.
Similar results were obtained for S. aureus–induced expres-
sion of CD11b and CD35 on monocytes, where combined inhi-
bition of CD14 and complement clearly outperformed the
combination of compstatin Cp40 with eritoran, again indicating
that anti-CD14 mediates effects beyond TLR4-MD2 inhibition.
However, inhibition with anti-CD14 alone did not show an in-
hibitory effect under these conditions.
Granulocyte activation and phagocytosis of E. coli and S. au-
reus by monocytes and granulocytes were largely complement
dependent, consistent with earlier observations [20, 28]. Inter-
estingly, inhibition of CD14 alone was more efficient than eri-
toran alone in reducing monocyte phagocytosis of E. coli. In
addition to phagocytosis, a possible effect of the various inhib-
itors on plasma bacterial lysis could be of importance for the
effect observed on the inflammatory reaction. Working with
heat-inactivated bacteria precludes use of colony-forming
units as a readout. However, we have previously shown that in-
hibition of CD14 did not reduce the killing of live E. coli in
porcine whole-blood specimens, whereas inhibition of C3 re-
duced but did not abolish bacterial killing [29]. This effect of
complement inhibition might reduce the amount of plasma
LPS and thus attenuate the cytokine storm.
There was much optimism expressed surrounding eritoran
and its potential to reduce mortality in sepsis. Yet, again, when
the phase 3 trial was concluded, no improvement was seen in
28-day mortality [11]. Savva et al pointed out that merely inhib-
iting a single pattern-recognition receptor could be insufficient,
since other receptors might fill in for TLR4, particularly when
gram-positive bacteria are involved, thus overriding the inhibito-
ry effect [30]. We have hypothesized that a combined inhibitory
approach is necessary in sepsis. Indeed, when comparing com-
bined CD14 and complement inhibition to inhibition by eritoran
alone, as tested in clinical trials, the combined approach was vast-
ly more efficient in our model. Furthermore, our data indicate
that complement and CD14 inhibition combined would be
more efficient than combining a complement inhibitor with eri-
toran. This warrants further validation in animal studies.
Development of new treatments for sepsis has proven diffi-
cult, demonstrating the discrepancies between preclinical
Figure 6. Inhibition of Staphylococcus aureus–induced upregulation of CD11b and CD35 on monocytes and granulocytes in human whole-blood specimens. Upregulation of
CD11b and CD35 on monocytes and granulocytes in response to incubating human whole-blood specimens with heat-inactivated S. aureus (1 × 108 bacteria/mL) for 20 minutes
after preincubation with phosphate-buffered saline (PBS), compstatin (Cp40), anti-CD14, eritoran, anti-CD14 plus compstatin, or eritoran plus compstatin. Data are shown as
median fluorescence intensity (MFI). Data presentation and statistics are as described in the legend to Figure 3. **P < .01 and ****P < .0001. Abbreviation: NS, nonsignificant.
148 • JID 2016:214 (1 July) • Gustavsen et al
models and clinical outcomes. There are obvious shortcomings
in our model, particularly the pretreatment approach, because
most patients would not receive medications at such an early
stage. However, finding complex human systems that can better
reflect the clinical effects of treatments is important to improve
the selection of therapies for clinical trials. Here we demonstrate
important shortcomings of TLR4-MD2 inhibition alone, partic-
ularly in gram-positive inflammation; this conclusion corre-
sponds to clinical findings. Thus, the whole-blood model
could be a promising tool for identifying potential therapeutic
approaches to complex inflammatory diseases.
Although E. coli and S. aureus are the leading causative
agents in sepsis, a long list of other microbial pathogens can
be found, including the setting of polymicrobial infections, un-
derscoring the need for targeting broad-acting pattern-recogni-
tion receptors and upstream in the recognition systems. We
have recently demonstrated that the importance of combined
inhibition, as compared to inhibition by anti-CD14 alone,
also increases with incremental doses of E. coli [31]. Since septic
patients have an overwhelming dysregulation of the inflamma-
tory system, one might suspect that the benefits of combined
inhibition instead of single-agent inhibition would be even
more pronounced in that setting. Thus, in conclusion, we
have shown that a combined inhibition strategy against CD14
and complement might be a promising treatment for human
sepsis.
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